Hesperidin methylchalcone
Cat. No.：YN410034
| 产品名称: | Hesperidin methylchalcone |
| CAS No.: | 24292-52-2 |
| Chemical Name: | (E)-1-[4-[[6-O-(6-Deoxy-α-L-mannopyranosyl)-β-D-glucopyranosyl]oxy]-2-hydroxy-6-methoxyphenyl]-3-(3-hydroxy-4-methoxyphenyl)-2-Propen-1-one, , 2',3,4'-Trihydroxy-4,6'-dimethoxychalcone; 4'-[6-O-(6-Deoxy-α-L-mannopyranosyl)-β-D-glucopyranoside]; Hesperidin |
| Synonyms: | Hesperidin Methyl Chalcone; Hesperidin methylchalcone; |
| 分子量: | 624.59 |
| 分子式: | C₂₉H₃₆O₁₅ |
| SMILES: | COC1=C(C(/C=C/C2=CC(O)=C(OC)C=C2)=O)C(O)=CC(O[C@H](O3)[C@H](O)[C@@H](O)[C@H](O)[C@H]3CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)=C1 |
| 存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
| 运输: | Room temperature in continental US; may vary elsewhere. |
| 产品描述: | Hesperidin methylchalcone (Hesperidin methyl chalcone) 抑制氧化应激，细胞因子产生和NF-κB活化。Hesperidin methylchalcone 抑制炎症和疼痛。且具有血管保护活性。 |
| IC50和靶点: | |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: |
Bouskela, E. et al.: J. Cardio. Pharmacol., 22, 225 (1993)
